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ABSTRACT
Background. Diabetes is an emerging chronic disease in developing countries. Its
management in developing countries is mainly hospital/clinic based. The increasing
diabetes burden in developing countries provides opportunities for community
pharmacists to deliver a range of services. Since the management of diabetes requires
the patient’s own involvement, it is important to gain their views in order to develop
pharmacy-based diabetes services. Studies on diabetes patients’ views have been
limited to developed countries.
Objectives. To investigate, within a developing country setting (Indonesia), current
use of pharmacy services by type 2 diabetes patients, and to evaluate their views
regarding community pharmacists’ roles, and the characteristics that influence their
views.
Methods. A questionnaire survey was conducted within 10 purposefully selected
community pharmacies in Surabaya, Indonesia. Each pharmacy recruited
approximately 20 patients seeking antidiabetic medications. Usage of pharmacy
services was identified using binary responses (‘yes’/‘no’) and views on pharmacists’
roles were rated using Likert scales; an open-ended question was used to identify
patient perceived priority roles. Logistic regression models were used to determine
characteristics associated with patients’ views.
Results. A total of 196 pharmacy patients with type 2 diabetes responded (58.3%
response rate). Most patients used community pharmacies for dispensing (100%)
and education on how to use medications (79.6%). There were mixed views towards
pharmacists providing services beyond dispensing. The highest priorities identified
were from the ‘patient education’ domain: education on medications (i.e., directions
for use (64.5%), storage (26.6%), common/important adverse effects (25.5%)); and
the ‘monitoring’ domain: monitoring medication compliance (37.3%). Patients
with higher incomes or who were working were less supportive of these expanded
services, whereas patients who previously used a service, those with risk factors for
complications or having poor/unknown glycaemic control were more supportive.
Conclusions. Community pharmacies in Surabaya, Indonesia in this study were
mainly utilised for dispensing. However, many type 2 diabetes patients using these
How to cite this article Wibowo et al. (2015), An evaluation of community pharmacy-based services for type 2 diabetes in an Indonesian
setting: patient survey. PeerJ 3:e1449; DOI 10.7717/peerj.1449
pharmacies report limited monitoring of blood glucose levels and poor glycaemic
control, which indicates an opportunity for greater pharmacist involvement. Yet
for this to occur, patients’ limited expectations of pharmacists roles will need to be
broadened. Characteristics influencing these views should inform the development
of pharmacy-based diabetes services in the environment of the burgeoning burden of
diabetes.
Subjects Diabetes and Endocrinology, Evidence Based Medicine, Health Policy
Keywords Pharmacy services, Indonesia, Community pharmacy, Diabetes, Patient views
INTRODUCTION
Indonesia is a major developing country with a population of 237.6 million (International
Diabetes Federation , 2013), and is among the top 10 countries in the world according to the
number of people with diabetes (Fowler, 2008). In 2013, it was estimated that 8.5 million
people in Indonesia were living with diabetes, and this number is expected to increase to
14.1 million by 2035 (Fowler, 2008). Diabetes in Indonesia is currently managed in hospital
outpatient or clinic settings (Soewondo et al., 2010; Soewondo, Ferrario & Tahapary, 2013).
An increased number of people with diabetes will require more community-based care,
providing an opportunity for community pharmacists to deliver a range of diabetes
services. While the 2012 Indonesia Health Profile reported a total of 17,613 pharmacies
(mainly community-based) (Kementrian Kesehatan Republik Indonesia, 2013), Indonesian
community pharmacies currently have limited roles within Government insurance plans,
providing services mainly to the private sector (Wang et al., 2009).
The introduction of Standards for Pharmaceutical Care in Community Pharmacies
in 2006 has emphasised the need for community pharmacists to be involved in the
care of patients with chronic diseases, including diabetes (Kementrian Kesehatan
Republik Indonesia, 2006). The standards included a range of services, i.e., prescription
medication service (i.e., prescription review, drug dispensing/supply, drug information
and counselling, and monitoring), health promotion and education to promote self-care,
and home/residential care (Kementrian Kesehatan Republik Indonesia, 2006). A previous
study involving a survey of community pharmacists in Surabaya, Indonesia reported
despite community pharmacists’ expressed willingness to take up a broader role in
diabetes care, the majority performed limited services beyond dispensing (Wibowo
et al., 2015). Studies in developed countries (such as the UK, the USA, Canada and
European countries), however, reported that more than 50% of community pharmacies
have provided extended services for diabetes patients, including: education related to
medications, lifestyle education, supporting patients in performing self-monitoring of
blood glucose (SMBG), and monitoring compliance with medications (Simpson et al.,
2009; Douglas, Power & Hudson, 2007; Abduelkarem et al., 2003b; Younis, Campbell & Slack,
2001; Kjome, Sandberg & Grana˚s, 2008; Plake, Chesnut & Odorzynski, 2007; Storimans,
2005; Timmer et al., 1999).
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To increase the uptake of pharmacy-based services amongst diabetes patients in Indone-
sia, it is important to understand the perspectives of diabetes patients on pharmacy-based
services that would assist with their care. This is especially so since diabetes is a chronic
disease that requires daily care in the hands of patients (Abduelkarem et al., 2003a). Several
studies have been conducted to investigate diabetes patient views regarding aspects of
community pharmacists’ roles; however, these have thus far been limited to developed
countries, such as the UK and the USA (Abduelkarem et al., 2003a; Weitzman et al., 2009;
Brown & Green, 2000; Hermansen-Kobulnicky & Worley, 2008; Twigg et al., 2013). Two
previous small studies conducted in community pharmacies in Indonesia, although not
specific to diabetes patients, have found that general patients had positive perceptions of
pharmacy services, providing facilitation for pharmacists to develop their professional
roles (Handayani & Raharni, Gitawati, 2009; Abdullah, Andrajati & Supardi, 2010).
This present study aimed to investigate, within an Indonesian setting, the current use of
community pharmacy services by patients with type 2 diabetes, and to evaluate their views
on the potential roles of community pharmacists, and the characteristics that influence
their views. The results of the study should inform the Government, professional bodies,
and practitioners on the development of pharmacy-based diabetes services in a developing
country setting (Indonesia).
METHODS
This study was approved by the Human Research Ethics Committee of Curtin University
(PH-09-11) and Ikatan Apoteker Indonesia—IAI (Indonesian Pharmacists Association)
(001/SK/BPD-IAI/SURABAYA/2010).
Setting and sample recruitment
The aims of the study included the estimation of the prevalence of service usage and patient
views. A sample size of 200 was defined which if broadly representative of the population
of pharmacy patients with type 2 diabetes in Surabaya, the 95% confidence intervals for
the true prevalence estimates would be within 7% of the figures obtained from the sample
(based on a prevalence estimate of 50%). For the analysis of characteristics associated
with respondents’ views, a sample of 200 would be expected to be adequate to identify
any independent variables exhibiting a moderate to small effect size (with power= 80%,
α = 0.05) (Tabachnick & LS Fidell, 2007).
A previous pharmacist survey had been conducted on a random sample of 400 commu-
nity pharmacies in Surabaya (60% response rate), providing data on the characteristics
of the community pharmacies and diabetes services provided (reported elsewhere)
(Wibowo et al., 2015). Based on the pharmacy characteristics data, 10 community
pharmacies were purposefully selected as sampling sites in this study, aiming to include
different geographical areas and socio-economic levels in Surabaya. Surabaya consists of
31 sub-districts which can be categorised into five geographical areas, namely: centre,
west, east, north and south; and four socio-economic levels, from high (labelled ‘1’)
to low (labelled ‘4’) (Nugroho, 2010). Each pharmacy was responsible for recruiting
approximately 20 patients. Patients eligible for the survey were those aged over 18 years,
Wibowo et al. (2015), PeerJ, DOI 10.7717/peerj.1449 3/19
with a diagnosis of type 2 diabetes for which they were receiving oral antidiabetic
medications. Patients were recruited as they were seeking oral antidiabetic medications
at these pharmacies, and their written consent was obtained.
Data collection
Questionnaire development
The survey questionnaire consisted of four sections: (A) patient demographics, (B)
services for type 2 diabetes patients—use of services and views on pharmacists’ roles,
(C) diabetes profile, and (D) monitoring profile. The questionnaire cover page contained
information about the study and a consent form. Section B of the questionnaire contained
a list of services for type 2 diabetes patients that was drafted based on a generic model
generated from the literature (Perkumpulan Endokrinologi Indonesia, 2011; Power et al.,
2006; Diabetes Australia, 2012; American Diabetes Association, 2013; Department of Health
Western Australia, 2008). A binary choice question was used to capture patient usage
of each service (‘yes’/’no’), and a 6-point Likert scale was used to reflect patient views
on pharmacists’ roles (1 = definitely no, 6 = definitely yes). This was followed by an
open-ended question to explore patient priorities regarding their views of pharmacist
roles: ‘In your opinion, what are the five most important services that should be provided
at pharmacies to assist you with your diabetes?’ The questionnaire was face and content
validated by a panel of seven academics, two board members of the IAI, two Indonesian
community pharmacists and two diabetes patients. Their feedback, where appropriate, was
incorporated into the questionnaire.
The questionnaire (English version) then went through a translation process to an
Indonesian version: (i) forward translation to Bahasa Indonesia by one of the investi-
gators whose first language is Bahasa Indonesia; (ii) back-translation to English by an
independent English first-language translator; and (iii) the back-translation was compared
to the original version by two of the investigators whose first language was English. The
forward-translation questionnaire was piloted by 10 type 2 diabetes patients. This resulted
in minor changes to the final questionnaire. To assess reliability, the questionnaire was
distributed on two occasions separated by a two-week interval. Responses to the Likert
scales were grouped (ratings of 1–4, and ratings of 5–6) to ensure that Kappa was able to be
calculated; the resulting Kappa scores for diabetes services (Section B) ranged from 0.412
to 1.000, which were classified as ‘acceptable’ to ‘excellent’ levels of test–retest reliability
(Landis & Koch, 1977).
Questionnaire administration
Owners of the 10 selected pharmacies were approached. In the case of refusal, that
pharmacy was replaced with another pharmacy in the same geographical area and
socio-economic level (Table 1). At each pharmacy, 40 questionnaires were issued,
and the pharmacist and/or pharmacy staff member was briefed about the study and
how to complete the questionnaire. The pharmacist and/or the pharmacy staff member
was asked to explain about the study to the eligible patients and to invite them to
participate; each pharmacy aimed to recruit approximately 20 patients. Once completed,
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Table 1 Patient recruitment data from 10 community pharmacies.
Pharmacy code Geographical area Socio-economic level Average number
of diabetes patients
per month
Number of
questionnaires
distributed
Number of useable
questionnaires
returned
Pharmacy 1 East Surabaya 2 150 40 21
Pharmacy 2 Central Surabaya 1 200 28 18
Pharmacy 3 East Surabaya 3 70 35 20
Pharmacy 4 West Surabaya 4 100 32 19
Pharmacy 5 South Surabaya 3 140 37 20
Pharmacy 6 Central Surabaya 2 100 30 20
Pharmacy 7 South Surabaya 4 100 36 20
Pharmacy 8 North Surabaya 1 240 31 19
Pharmacy 9 West Surabaya 3 120 40 20
Pharmacy 10 North Surabaya 2 100 27 19
Total 336 196
the questionnaire was placed in a sealed envelope by the respondent and submitted to the
pharmacist/pharmacy staff. The completed questionnaires as well as the remaining unused
questionnaires were then handed to the investigators by the agreed deadline.
Data analysis
Descriptive statistics were used to summarise the patient characteristics: demographics
(Section A), diabetes profile (Section C), and monitoring profile (Section D). SPSS version
19.0 was used to perform the analysis.
In relation to diabetes services (Section B), frequencies were calculated for binary
responses (‘yes’/’no’) related to the patient usage of services and for responses from Likert
scales related to the extent of patient agreement regarding pharmacists’ roles. Moreover,
content analysis was used for responses from the open-ended question to explore patient
views on the five priority services that should be provided at the pharmacies. An initial
coding frame structure was established from the generic model generated from the
literature. The responses were coded (if new codes emerged, they were added to the
thematic codes in the coding frame), and frequencies were calculated for each code (Rose,
Spinks & Canhoto, 2015).
It was of particular interest to identify characteristics associated with the views of
patients related to pharmacy-based diabetes services. For this reason, the responses
regarding patients’ views for each type of service were classified into binary variables,
to indicate ‘strong agreement’ (Likert scale ratings of 5–6) versus ‘ambivalence or
disagreement’ (Likert scale ratings of 1–4) that a service should be provided by the
pharmacy. These binary variables were used as dependent variables in logistic regression
models to identify patient characteristics associated with the strong support for each
role. Some roles were considered to be different aspects of an overarching role. For
example, the roles to provide information on: the taking of medications, use of insulin
devices, storage of medications, precautions, and adverse effects were all components of
‘medication education.’ In order to analyse characteristics associated with strong support
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for an overarching or ‘composite’ role, the arithmetic average of the Likert responses for
the component roles was calculated and then converted to a binary variable in a manner
similar to that used for the individual roles (scores of 5 or more were taken to indicate
strong support, otherwise ambivalence or low support). Taking the simple average of the
component roles implicitly gives equal weight to each of the roles within a composite. It
would have been preferable to use Factor Analysis to identify if some of the component
roles were more important than others, but the sample size was considered too small for
this refinement. It is generally recommended that sample sizes of 300 or more should be
used to obtain stable factor loadings (Tabachnick & LS Fidell, 2007). Patient characteristics
included as independent variables were gender, age, education, employment, income,
health insurance cover, diabetes organisation membership, duration of diabetes (time since
diagnosis), risk factors for complications, complications and diabetes (glycaemic) control.
The models also included an independent variable indicating patients’ previous use of
the service (binary responses: ‘yes’/’no’). For dependent variables which were ‘composite’
(for example ‘medication education’), the binary responses indicating previous use of
each component service were treated as numeric (zero for ‘No’, one for ‘Yes’), and their
mean was calculated and used in the model as an independent variable to show the degree
of previous use of the composite service. A mean value close to 1 indicated that most
components of the composite role had been used, while a lower value indicated less use.
A backward elimination strategy was used to identify all the variables which significantly
contributed to each model. Through this approach all independent variables were included
initially, and then the least significant variable was dropped (one at a time) until the
p-value associated with each of the variables remaining in the model was less than 0.05.
RESULTS
Sample recruitment
This study included 10 community pharmacies as sampling points after approaching 11
community pharmacies in Surabaya. One pharmacy refused, as the employee pharmacist
was planning to resign and they were in the process of recruiting a new one. From the
final 10 pharmacies, a total of 336 questionnaires were distributed and 204 were returned;
however, eight patients reported the use of insulin at the beginning of their therapies and
were deemed to have type 1 diabetes, leaving a sample size of 196 (a response rate of 58.3%)
(Table 1).
Characteristics of pharmacy patients with type 2 diabetes
The demographic information of participating patients (Section A) is summarised in
Table 2. Approximately 60% of respondents were female and half of respondents were aged
60 years or older. Approximately half of the respondents did not have health insurance
plans.
The diabetes data reported by participating patients (Section C) are shown in Table 3.
The median duration of diabetes (time since diagnosis) was seven years. More than 80% of
respondents reported that their treatment regimen included oral antidiabetic medications
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Table 2 Demographic data of patient respondents (N = 196).
Patient demographics Frequency (%)
Gender
Male 80 (40.8)
Female 116 (59.2)
Age, years—median (range) 60.0 (32–86)
Ethnicity
Asian 196 (100.0)
Others 0 (0.0)
Highest education
No schooling 6 (3.1)
Primary school 23 (11.7)
Junior high school 41 (20.9)
Senior high school 71 (36.2)
Diploma 18 (9.2)
Bachelor degree 25 (12.8)
Postgraduate degree 12 (6.1)
Employment status
Working full-time (≥40 hours/week) 53 (27.0)
Working part-time (<40 hours/week) 20 (10.2)
Not working 123 (62.8)
Total household income (from all sources) per montha
≤Rp 2 million 103 (52.6)
>Rp 2 million—5 million 54 (27.6)
>Rp 5 million—10 million 25 (12.8)
>Rp 10 million 12 (6.1)
Health insurance
Self-sponsored insurance 31 (15.8)
Employer-sponsored insurance 56 (28.6)
Insurance scheme for the poor/near poor 9 (4.6)
No insurance 100 (51.0)
Member of a diabetes organisation
Yes 74 (37.8)
No 122 (62.2)
Notes.
Abbreviations: Rp, Indonesian rupiah.
a 2 missing responses.
and diet modifications. It is important to note that this variable did not measure whether
the doctor made the medication/diet/exercise recommendations, but rather whether the
patient remembered and/or reported it. Almost 60% of the respondents reported having at
least one diabetes-related complication, and most of the patients reported having at least
one risk factor for complications.
Table 4 shows the monitoring profile reported by participating patients (Section D).
HbA1c refers to glycosylated hemoglobin, which identifies average plasma glucose
concentration over the previous three months. To provide insight to patients’ diabetes
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Table 3 Self-reported diabetes and health profile of patient respondents (N = 196).
Patient diabetes profile Frequency (%) of ‘yes’
Duration of diabetes, years—median (range)a 7 (1–42)
Current diabetes treatment
Modifying diet 173 (88.3)
Exercise programme 123 (62.8)
Oral antidiabetic medication 189 (96.4)
Insulin 44 (22.4)
Risk factorsc 157 (80.1)
BMI ≥25 kg/m2b 88 (44.9)
(History of) smoking 41 (20.9)
High cholesterold 77 (39.5)
High blood pressuree 104 (53.6)
Complicationsc 115 (58.7)
Heart disease 34 (17.3)
Eye problems 52 (26.5)
Foot discomfort 81 (41.3)
Foot ulcers 14 (7.1)
Kidney problems 16 (8.2)
Notes.
a Some missing responses.
b BMI, body mass index = weight (kg) divided by height2 (m2); some missing responses.
c Respondents responded ‘yes’ for at least one complication/risk factor.
d Respondents responded ‘yes’, either for “Do you have high cholesterol?” or “Do you take medications to treat your high
cholesterol?”, or for both.
e Respondents responded ‘yes’, either for “Do you have high blood pressure?” or “Do you take medications to treat your high
blood pressure?”, or for both.
(glycaemic) control, variables related to the symptoms of hypo/hyperglycaemia and
HbA1c values were combined to indicate: fair-good control (i.e., no symptoms and HbA1c
≤8.0%); poor control (i.e., presence of symptoms and/or HbA1c >8.0%); and unknown
(i.e., symptoms ‘none/don’t know’ and/or HbA1c values ‘none/don’t know’). Using this
derived variable, most respondents were perceived to have either poor diabetes control
(45.9%) or unknown diabetes control (42.3%).
Patients’ use of pharmacy services and their views on pharmacist
roles
Responses describing patient usage of pharmacy services are summarised in Table 5. In
addition to the traditional role of dispensing (‘treatment administration’), the most
frequent services received were ‘patient education’ about medications, particularly
directions for use (79.6%) and special precautions to follow (71.9%).
Table 5 also shows responses regarding pharmacists’ roles. All patients agreed with
pharmacists’ roles in dispensing. Beyond dispensing, more than 70% of respondents
expected pharmacists to provide ‘patient education’ about medications. About half of
respondents supported other activities related to ‘patient education’ and ‘monitoring’.
There were large gaps between patient usage and expectation regards education on:
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Table 4 Self-reported monitoring profile of patient respondents (N = 195).a
Patient monitoring Frequency (%) of ‘yes’
Diabetes (glycaemic) control
High blood sugar reactions (in the last month) 56 (28.7)
Low blood sugar reactions (in the last month) 43 (22.1)
Severe blood sugar reactions (in the last year) 26 (13.3)
HbA1c last value 53 (27.0)b
<6.5% 18
6.5–8% 27
>8% 8
Routine tests
SMBG (in the last week) 74 (37.9)
Medical monitoring (in the last 3 months)
Blood sugar 167 (86.1)
Blood pressure 166 (85.1)
Weight 124 (63.9)
HbA1c measurement (in the last year) 65 (33.3)
Medical monitoring (in the last year)
Cholesterol 127 (65.1)
Kidney 84 (43.1)
Eyes 48 (23.2)
Feet 41 (21.0)
Notes.
Abbreviations:: SMBG, self-monitoring of blood glucose; HbA1c, glycosylated haemoglobin.
a 1 missing response.
b Number of respondents reported their HbA1c last value.
medication storage and adverse effects, SMBG, prevention of complications, need for
regular monitoring, and foot care. In addition, patients expected pharmacists to provide
more monitoring services than those currently provided.
In terms of the priority roles of pharmacists, patients’ responses can be seen in Table 6.
The top five services perceived by patients as priorities (in addition to pharmacists’
traditional roles of dispensing being already provided) were from the ‘patient edu-
cation’ domain—education related to medications (i.e., directions for use (64.5%),
common/important adverse effects (25.5%), storage requirements (26.6%)) and the
‘monitoring’ domain—monitoring compliance with medications (37.3%). No new ser-
vices were raised, beyond those already listed in the questionnaire, from this open-ended
question, suggesting that from the respondents’ perspective the range of services that
should be provided by community pharmacies described in Table 5 was complete.
Characteristics associated with patients’ views on pharmacist
roles
Logistic regression models were used to identify patient characteristics which were
associated with patients’ views on pharmacists’ roles. The odds ratios of significant
characteristics are summarised in Table 7.
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Table 5 Patients’ use of community pharmacy services and their views on pharmacists’ roles (N =
196).
Services Being used
N (%)
Being viewed as
pharmacist rolesa
N (%)
Treatment administration
Prepare medications 196 (100) 195 (100)
Provide labels with instructions for use 196 (100) 195 (100)
Patient education
Disease process 93 (47.4) 120 (61.5)
Treatment targets 79 (40.3) 115 (59.0)
Antidiabetic medications:
Directions for use 156 (79.6) 160 (82.1)
Use of insulin devicesb 27 (61.4) 142 (72.7)
Storage requirements 93 (47.4) 144 (73.9)
Special precautions to follow 141 (71.9) 155 (79.5)
Common/important adverse effects 87 (44.4) 139 (71.3)
Exercise 66 (33.7) 96 (49.2)
Diet 84 (42.9) 101 (51.8)
SMBG 63 (32.1) 107 (54.9)
Prevention/treatment of acute complications 67 (34.2) 126 (64.6)
Prevention/treatment of chronic complications 45 (23.0) 116 (59.5)
Need for regular medical monitoring 48 (24.5) 97 (49.8)
Foot self-care 35 (17.9) 95 (48.7)
Smoking cessationc 12 (29.3) 72 (36.7)
Monitoring
Monitor compliance with:
Antidiabetic medications 100 (51.0) 127 (65.1)
Exercise plan 62 (31.6) 102 (52.3)
Diet plan 78 (39.8) 109 (55.9)
Plan for prevention/treatment of chronic
complications
44 (22.4) 92 (47.2)
Scheduled medical monitoring 38 (19.4) 96 (49.3)
Monitor treatment outcomes:
Check records on SMBG 58 (29.6) 101 (51.8)
Carry out blood glucose tests 58 (29.6) 113 (58.0)
Measure BMI 40 (20.4) 89 (45.6)
Measure blood pressure 55 (28.1) 103 (52.8)
Check results on patient laboratory tests 51 (26.0) 98 (50.3)
Monitor for adverse effects 63 (32.1) 110 (56.4)
Review
Refer patients if necessary 69 (35.2) 110 (56.5)
Notes.
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index.
a 1 missing response.
b The percentage was calculated for patients currently/previously taking insulin (N = 44).
c The percentage was calculated for patients currently (or had a history of) smoking (N = 41).
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Table 6 Patients’ open-ended views on priority roles of pharmacists in diabetes care (N = 169).a
Priority servicesb Number of responses (%)
Treatment administration
Prepare medications 35 (20.7)
Provide labels with instructions for use 66 (39.1)
Patient education
Disease process 27 (16.0)
Antidiabetic medications:
Directions for use 109 (64.5)
Use of insulin devices 15 (8.9)
Storage requirements 45 (26.6)
Special precautions to follow 37 (18.9)
Common/important adverse effects 50 (25.5)
Exercise 27 (13.8)
Diet 33 (16.8)
Prevention/treatment of acute complications 27 (16.0)
Prevention/treatment of chronic complications 20 (11.8)
Monitoring
Monitor compliance with:
Antidiabetic medications 63 (37.3)
Monitor treatment outcomes:
Carry out blood glucose tests 30 (17.8)
Measure blood pressure 25 (14.8)
Monitor for adverse effects 23 (13.6)
Others (not a specific service)
Provide a complete range of medications 12 (7.1)
Information about medications 16 (9.5)
Notes.
Responses to an open-ended question:“In your opinion, what are the five most important services that should be provided
at pharmacies to assist you with your diabetes?”
a From a total 196 respondents, there were 26 missing responses and 1 invalid response, giving a total N = 169.
b Services selected by more than 10 respondents.
Patient experience (previous use) with a service was strongly associated with their views
that the service should be provided by pharmacists (Odds Ratios (ORs) 4.4–11.3). Patients
with poor/unknown glycaemic control or those who had risk factors for complications
were more supportive of pharmacists providing some monitoring services (ORs 2.3–10.2).
On the other hand, patients with higher incomes or those who were working were less
supportive towards pharmacists providing some education and monitoring services
(ORs 0.2–0.5).
DISCUSSION
This study has found most type 2 diabetes patients recruited had complications and/or
risk factors for complications (80.1% and 58.7%, respectively), and/or had poor/unknown
glycaemic control (45.9% and 42.3%, respectively). It is evident that in the current hospital
outpatient/clinic treatment model many patients were poorly monitored. This is consistent
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Table 7 Odds ratios and 95% confidence intervals of significant characteristics associated with support for ‘patient education’ and ‘monitoring’ by pharmacists.
Patient education by pharmacists Monitoring by pharmacists
N Medicationsa Exercise Diet All educationb Compliance Treatment outcomes Adverse drug
reaction
Perform clinical
testingsd
Check test resultse
Income
Low 105 Reference Reference Reference Reference Reference Reference
Moderate 54 NS 0.4 (0.17–0.90) NS NS NS NS
High 37 0.3 (0.10–0.72) 0.3 (0.10–0.80) 0.3 (0.12–0.61) 0.3 (0.10–0.68) 0.3 (0.10–0.72) 0.2 (0.09–0.53)
Employment
Not working 123 Reference Reference Reference Reference Reference
Working 73 0.3 (0.15–0.83) 0.5 (0.24–0.94) 0.4 (0.21–0.88) 0.5 (0.24–0.97) 0.3 (0.15–0.74)
Risk factors
No 39 Reference
Yes 157 3.4 (1.46–8.03)
Diabetes
(glycaemic) controlf
Good/fair 23 Reference Reference Reference
Poor 90 NS 4.9 (1.20–20.55) 3.2 (1.05–9.97)
Unknown 83 2.3 (1.22–4.51) 10.2 (2.44–42.95) 4.3 (1.36–13.57)
Previous use
of the service
No g Reference Reference Reference Reference Reference Reference Reference Reference
Yes 4.5 (1.79–11.53) 10.3 (4.6–23.15) 4.4 (2.30–8.30) 4.5 (1.60–12.51) 5.2 (1.79–11.52) 13.6 (5.21–35.51) 11.3 (4.51–28.13) 6.3 (2.82–13.90)
Notes.
a A composite variable—education related to antidiabetic medications: directions for use, use of insulin devices (calculated only from those currently/previously taking insulin), storage, special precautions
and common/important adverse effects; a mean rating ≥5 was used.
b A composite variable—all education: disease process, treatment targets, antidiabetic medications, exercise, diet, self-monitoring of blood glucose, prevention/treatment of acute complications, preven-
tion/treatment of chronic complications, need for regular monitoring, foot self-care and smoking cessation (calculated only from those currently, or had a history of, smoking); a mean rating ≥5 was
used.
c A composite variable—monitoring compliance with: antidiabetic medications, exercise and diet plan, plan for prevention/treatment of complications and scheduled medical monitoring; a mean rating
≥5 was used.
d A composite variable—perform clinical testings (measuring blood glucose, blood pressure and BMI); a mean rating ≥5 was used.
e A composite variable – check test results (patient self-monitoring records and laboratory data); a mean rating ≥5 was used.
f Diabetes (glycaemic) control is a composite variable of hyper/hypoglycaemia symptoms and HbA1c values.
g Numbers differ for each endpoint (service).
NS, not significantly different from the reference.
W
ib
o
w
o
et
al.(2015),P
eerJ,D
O
I10.7717/p
eerj.1449
12/19
with a population study of type 2 diabetes patients in Indonesia which reported that 67.9%
of type 2 diabetes patients had not achieved good glycaemic control (HbA1c<7.0%), and
approximately 60% of the patients had complications and/or risk factors for complications
(i.e., dyslipidaemia and/or hypertension) (Soewondo et al., 2010).
Moreover, this study reported that follow-up care tended to be inadequate, with
only about one-third of respondents reporting annual HbA1c monitoring and eye or
foot examinations. Supporting this finding, the Patient and Health Provider Survey in
Indonesia (2012) indicated that the majority of patients had not received foot or eye
examinations within the past year, only 30% had had their HbA1c checked and many
had expressed a wish to see health care providers more often (Novo Nordisk, 2013). It was
suggested that this poor quality of care and patient outcomes might relate to the lack of
awareness of, accessibility to and affordability of diabetes care for this patient group (Novo
Nordisk, 2013). Together with the findings of this study, it provides a basis for community
pharmacists to provide a range of services.
Patients’ use of pharmacy services and their views on pharmacist
roles
This study indicated little involvement of Indonesian community pharmacies in the care of
patients with type 2 diabetes. Respondents mostly utilised pharmacists for their supply role
(dispensing). A previous Indonesian study has confirmed the limited services provided to
general pharmacy patients (Handayani & Raharni, Gitawati, 2009).
Amongst non-supply roles, many respondents chose roles closely related to dispensing
as the priority roles of pharmacists, i.e., education related to medications, and monitoring
compliance with medications. Similar findings were evident from some international
studies involved diabetes patients (Abduelkarem et al., 2003a; Weitzman et al., 2009; Brown
& Green, 2000; Hermansen-Kobulnicky & Worley, 2008; Twigg et al., 2013). Two qualitative
studies indicated that patients identified the primary expertise of the community phar-
macist as medicines supply, and there were mixed perceptions of community pharmacists’
roles extending to advising on prescription medicines, providing disease-related/health
advice or providing monitoring services (using clinical testing devices) (Twigg et al., 2013;
Gidman & Cowley, 2013).
It is interesting that the responses to the open-ended question that patients perceived
that services related to dispensing and patient education were those that should be
provided to type 2 diabetes patients from community pharmacies (Table 6). All of those
they considered should be provided had been included in the options that could be
provided (Table 5). This also indicated that patients did not have additional requirements
for services not identified initially for this study.
Characteristics associated with patients’ views on pharmacist
roles
The logistic regression models consistently found that a patient’s support for a service
was influenced by their experience (previous use) of the service (Odds Ratios, ORs≥4.4).
Supporting this finding, studies worldwide have shown that type 2 diabetes patients have
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increased perceptions of pharmacists’ ability to assist them after receiving pharmacy-based
services (Fera et al., 2008; Garrett & Martin, 2003; Hughes, 2006; Abduelkarem & Sackville,
2009; Hales et al., 2010). It should be emphasised that most patients in this study (at that
time) received limited services from community pharmacies, thus they might not be aware
of what pharmacists should and could do.
The implementation of Jaminan Kesehatan Nasional—JKN (National Health Coverage)
in 2014 provides the best opportunity to optimise the use of Indonesian community phar-
macies. It is important for the Government and IAI to establish an agreement on the basic
services that should be available in community pharmacies. While the current payment
under the scheme includes a very low prescription fee (Kementrian Kesehatan Republik
Indonesia, 2014), the IAI should negotiate adequate remuneration for pharmacists to
provide the services, thus enabling community pharmacies to remain viable.
In addition to patients’ past experiences, patients who were working and/or had higher
incomes were generally less supportive of some of the proposed education or monitoring
services (ORs ≤0.5). This might be because these groups of patients were likely to be
younger (mean age 63.7 years for non-workers versus 54.0 years for workers, p < 0.0001;
and mean age 60.4 years for income ≤Rp 5 million versus 58.6 years for income >Rp 5
million, p= 0.358). Two previous studies have reported that older patients, or those living
with diabetes for a long time, were more supportive of pharmacists’ contributions (Twigg
et al., 2013; Ibrahim, Al Tukmagi & Wayyes, 2013). It has been suggested that elderly people
are one of the groups whose need for additional advice on medications and other related
services has been demonstrated (Cartwright & Smith, 1988).
Notably, patients who had risk factors for complications and/or had poor/unknown
glycaemic control were much more supportive of pharmacists monitoring treatment
outcomes or adverse drug reactions (ORs ≥2.3). Such patients might reflect those with
lower health status, representing a target group who might be more motivated and
responsive to pharmacists’ involvement. It has been suggested that patients who benefit
most from pharmacist-led education/coaching and disease state management services
include those with poor glycaemic control and multiple comorbidities (Sisson & Kuhn,
2009). It is evident that overall treatment outcomes in this patient cohort are concerning
and expanding the community pharmacy role into patient management needs to be
investigated.
Limitations
The purposeful sampling method used in the study (20 patients from each of 10
pharmacies) was considered the only feasible manner by which it could be conducted.
The request for approximately 20 patients was to ensure that each pharmacy included a
range of patients in the sample and in many cases this about half of their current type
2 diabetes patients. No full list (sampling frame) of pharmacy patients with diabetes
exists in Surabaya, so it was not possible to obtain a truly random sample of patients
with this condition. Thus, there is a possibility of non-respondents not sharing the same
practice and/or views of respondents, and some caution should be exercised in generalising
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the findings. However, the pharmacies covered a wide range of settings (geographic and
socioeconomic), so that no particular background group of patients would be excluded;
and achieved a sound response rate of approximately 60%. The characteristics of the
respondents in this study were comparable to those of a population study involving all type
2 diabetes patients visiting 18 medical centres across Indonesia between November 2008
and February 2009 (N = 1,785) with respect to age (60 years versus 59 years, respectively),
gender (female 59.2% versus 55.2%, respectively), and duration of diabetes (7 years
versus 8 years, respectively) (Soewondo et al., 2010). Hence, although the sample is not
randomly selected and the risk of response bias might limit the generalisation, the views
of participants give some insight into the diabetes services used or desired at community
pharmacies in Surabaya.
CONCLUSIONS
Community pharmacies in Surabaya, Indonesia in this study are mainly utilised for their
basic services of dispensing. Many type 2 diabetes patients in these pharmacies reported
limited monitoring of blood glucose and poor glycaemic control; in addition, their follow-
up care and health outcomes were generally poor. These findings indicate a need and
opportunities for community pharmacists to provide a range of services for patients with
diabetes. Hence, strategies should be developed to broaden current pharmacy patients’
limited views of pharmacists’ roles which are mainly perceived as extensions to the supply
roles. It is evident that patients support the provision of services once they have been pro-
vided. Patient characteristics that influence these views provide a target group for imple-
mentation of a pharmacy-based diabetes service that should be evaluated. This can provide
a partial solution in the environment of a burgeoning burden of diabetes in Indonesia.
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